aTyr Pharma, Inc. (FRA:471A)

Market Cap	64.00M -80.4%
Revenue (ttm)	161.82K -19.1%
Net Income	-63.13M
EPS	-0.68
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	11
Open	0.5850
Previous Close	0.5750
Day's Range	0.5850 - 0.5850
52-Week Range	0.4680 - 5.7000
Beta	n/a
RSI	42.52
Earnings Date	May 1, 2026

About aTyr Pharma

aTyr Pharma, Inc., a clinical stage biotechnology company, engages in the discovery and development of product candidates that translate tRNA synthetase biology into new therapies for fibrosis and inflammation in the United States. Its lead therapeutic candidate efzofitimod, a selective modulator of NRP2 that is in Phase 3 clinical trial for the treatment of pulmonary sarcoidosis; Phase 2 clinical trial to treat Sarcoidosis and systemic sclerosis- interstitial lung disease (ILDs); and treatment of other ILDs, such as chronic hypersensitivity pn...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2005
• Employees: 59
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 471A

Financial Performance

In 2025, aTyr Pharma's revenue was $190,000, a decrease of -19.15% compared to the previous year's $235,000. Losses were -$74.12 million, 15.8% more than in 2024.

Financial numbers in USD